flipper and longfellow and Umibe et al., thanks all for your discussions. So, when IDH mutant patients are no longer GBM patients under the new definition of GBM by WHO but IDH wild are for whom DcVaxL is very effective, what a gift or blessing in disguise we got now; we don't have to look into the subgroups for trial efficacy like CVM is attempting and the fudsters lost their chance for fear mongering; I feel like DCVaxL wins efficacy in all 6 new Endpoints. Thanks again!
Market Data 
Markets 
AI
